1 The endocrine disruptor bisphenol A promotes nuclear ERRγ translocation, facilitating cell proliferation of Grade I endometrial cancer cells via EGF-dependent and EGF-independent pathways.

2 a novel approach for amplification and purification of mouse oligodendrocyte progenitor cells

3 Synthesis and biological evaluation of 2.4 nm thiolate-protected gold nanoparticles conjugated to Cetuximab for targeting glioblastoma cancer cells via the EGFR.

4 Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.

5 Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents.

6 NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim

7 Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing.

8 Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.

9 EGFR signaling in colorectal cancer: a clinical perspective

10 EGFR signaling in colorectal cancer: a clinical perspective

11 EGFR signaling in colorectal cancer: a clinical perspective

12 Retraction notice to “miR-613 inhibits proliferation and invasion of breast cancer cell via VEGFA” (Biochemical and Biophysical Research Communications (2016) 478(1) (274–278), (S0006291X16311469), (10.1016/j.bbrc.2016.07.031))

13 New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors.

14 miR-320/VEGFA axis affects high glucose-induced metabolic memory during human umbilical vein endothelial cell dysfunction in diabetes pathology.

15 Synthesis and preclinical investigation of Tc-p-SCN-Bzl-DTPA-cetuximab for targeting EGFR using head and neck squamous cell carcinoma (HNSCC) xenografts.

16 Effect of rutin on retinal VEGF, TNF-α, aldose reductase, and total antioxidant capacity in diabetic rats: molecular mechanism and ocular pharmacokinetics.

17 Profiling and Bioinformatic Analysis of Differentially Expressed Cytokines in Aqueous Humor of High Myopic Eyes - Clues for Anti-VEGF Injections.

18 Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model.

19 KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program

20 Interleukin 1 beta and Matrix Metallopeptidase 3 Contribute to Development of EGFR-dependent Serrated Polyps in Mouse Cecum.

21 Icariin and icaritin stimulate the proliferation of SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway.

22 A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant.

23 Cancer-targeted Nucleic Acid Delivery and Quantum Dot Imaging Using EGF Receptor Aptamer-conjugated Lipid Nanoparticles

24 Role of VEGF<inf>165b</inf>/VEGF<inf>TOTAL</inf> ratio in gestational diabetes mellitus

25 EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer.

26 Association of IGF1 and VEGFA polymorphisms with diabetic retinopathy in Pakistani population.

27 Modification of recombinant human epidermal growth factor (rh-EGF) expression vector by site directed mutagenesis for therapeutic protein production

28 Discovery of HB-EGF binding peptides and their functional characterization in ovarian cancer cell lines

29 Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.

30 In Vitro Angiogenic Properties of Plasmid DNA Encoding SDF-1α and VEGF165 Genes.

31 Correction: Kaempferol inhibits angiogenesis by suppressing hif-1α and vegfr2 activation via erk/p38 mapk and pi3k/akt/mtor signaling pathways in endothelial cells (Preventive Nutrition and Food Science (2017) 22: 4 (320-326)

32 Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.

33 EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling.

34 Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvIII in human glioblastomas.

35 Decreased eGFR Is Associated With Ischemic Stroke in Patients With Dilated Cardiomyopathy.

36 Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.

37 The heart of a hibernator: EGFR and MAPK signaling in cardiac muscle during the hibernation of thirteen-lined ground squirrels, .

38 Genetic interaction between placenta growth factor (PGF) and vascular endothelial growth factor A (VEGFA) in psoriasis.

39 miR-21-3p inhibits autophagy of bovine granulosa cells by targeting VEGFA via PI3K/AKT signaling.

40 Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors

41 Synthesis of Triazole-Substituted Quinazoline Hybrids for Anticancer Activity and a Lead Compound as the EGFR Blocker and ROS Inducer Agent

42 Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.

43 Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors.

44 Synthesis, molecular docking, and evaluation of novel bivalent pyrazolinyl-1,2,3-triazoles as potential VEGFR TK inhibitors and anti-cancer agents

45 ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.

46 EGFR signaling promotes β-cell proliferation and survivin expression during pregnancy.

47 Pathway focused protein profiling indicates differential function for IL-1B, -18 and VEGF during initiation and resolution of lung inflammation evoked by carbon nanoparticle exposure in mice.

48 Pathway focused protein profiling indicates differential function for IL-1B, -18 and VEGF during initiation and resolution of lung inflammation evoked by carbon nanoparticle exposure in mice

49 Plasma levels of soluble VEGF receptor isoforms, circulating pterins and VEGF system SNPs as prognostic biomarkers in patients with acute coronary syndromes

50 Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.

51 Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells.

52 Ibrutinib potentiates anti-hepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma.

53 Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m and negative proteinuria.

54 Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.

55 Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1α, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells.

56 Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.

57 Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

58 Distinct downstream signaling and the roles of VEGF and PlGF in high glucose-mediated injuries of human retinal endothelial cells in culture.

59 Asporin enhances colorectal cancer metastasis through activating the EGFR/src/cortactin signaling pathway

60 Dysregulation of VEGF-dependent angiogenesis in cavernous lung tuberculosis.

61 Effect of Moxibustion on HIF-1 and VEGF Levels in Patients with Rheumatoid Arthritis.

62 Vascular Endothelial Growth Factor A and VEGFR-1 Change during Preimplantation in Heifers.

63 The Role of VEGF and TNF-Alpha on Epithelialization of Diabetic Foot Ulcers after Hyperbaric Oxygen Therapy.

64 CD93 hematopoietic stem cells improve diabetic wound healing by VEGF activation and downregulation of DAPK-1

65 [A differentiated approach to analysis of retinal fluid and assessment of its effect on anti-VEGF therapy of neovascular age-related macular degeneration].

66 Effect of ovarian follicular fluid peptide (OFFP) on FSH and EGF binding to granulosa cells

67 EGF-containing Membrane-bound Mucins: a hidden ErbB2 targeting pathway?

68 Corrigendum to ‘Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2’ [European journal of medicinal chemistry 158 (2018) 814–831](S0223523418308225)(10.1016/j.ejmech.2018.09.050)

69 Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.

70 Long non-coding RNA NEAT1 promotes colorectal cancer progression by regulating miR-205-5p/VEGFA axis.

71 Prospective pediatric study comparing glomerular filtration rate estimates based on motion-robust dynamic contrast-enhanced magnetic resonance imaging and serum creatinine (eGFR) to Tc DTPA.

72 A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma

73 Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.

74 Extracellular vesicles derived from human adipose-derived stem cells promote the exogenous angiogenesis of fat grafts via the let-7/AGO1/VEGF signalling pathway

75 Matrine alleviates neurobehavioral alterations via modulation of JNK-mediated caspase-3 and BDNF/VEGF signaling in a mouse model of burn injury.

76 Correction to: EGFR signaling augments TLR4 cell surface expression and function in macrophages via regulation of Rab5a activation.

77 Tumor induction of VEGF promoter activity in stromal cells

78 Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDH wt astrocytoma to glioblastoma

79 Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines

80 mir-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating adam9 and vegf-a

81 role of copper and vascular endothelial growth factor (vegf) on endometrial angiogenesis

82 treatment of corneal neovascularization using anti-vegf bevacizumab

83 a high expression egfr/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening egfr antagonists from rhizoma polygoni cuspidati

84 quantitative analysis of [11c]-erlotinib pet demonstrates specific binding for activating mutations of the egfr kinase domain

85 severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring egfr mutation

86 serum zag levels were associated with egfr mild decrease in t2dm patients with diabetic nephropathy

87 the relationship between vegfa and tgfb1 polymorphisms and target lesion revascularization after elective percutaneous coronary intervention

88 effects of nerve growth factor (ngf) on blood vessels area and expression of the angiogenic factors vegf and tgfbeta1 in the rat ovary

89 effects of fundus laser combined with anti-vegf therapy on serum levels of nos, vegf and il-6 in patients with diabetic macular edema

90 effect of vegf on inflammatory regulation, neural survival, and functional improvement in rats following a complete spinal cord transection

91 synthesis, molecular docking and biological evaluation of glycyrrhizin analogs as anticancer agents targeting egfr

92 isogenic fus-egfp ipsc reporter lines enable quantification of fus stress granule pathology that is rescued by drugs inducing autophagy

93 tyrosine kinase inhibitors in egfr-mutated large-cell neuroendocrine carcinoma of the lung a case report

94 effects of pistacia atlantica resin oil on the level of vegf, hydroxyproline, antioxidant and wound healing activity in stz-induced diabetic rats

95 egfr protein expression using a specific intracellular domain antibody and pten and clinical outcomes in squamous cell lung cancer patients with egfr-tyrosine kinase inhibitor therapy

96 tgf-β and hypoxia/reoxygenation promote radioresistance of a549 lung cancer cells through activation of nrf2 and egfr

97 hmgb1 protects the heart against ischemia–reperfusion injury via pi3k/akt pathway-mediated upregulation of vegf expression

98 crude fucoidan extracts impair angiogenesis in models relevant for bone regeneration and osteosarcoma via reduction of vegf and sdf-1

99 vascular endothelial growth factor and its soluble receptors vegfr-1 and vegfr-2 in the serum of patients with systemic lupus erythematosus

100 formyl peptide receptor 1 modulates endothelial cell functions by nadph oxidase-dependent vegfr2 transactivation

101 long-lasting effects of anti-vegf/photodynamic combination therapy in the treatment of exudative age-related macular degeneration: a retrospective chart review

Keyword Connections

Journals

Research Groups

Bibliographies